1

OUR MISSION To reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating access of new, effective and affordable anti-malaria medicines. 2  60 people Geneva-based 300 partners Africa 67 Americas 89 Asia-Oceania 70 Europe projects In pipeline Research 21 Translational 9 Phase IIB/III 5 4 products launched >210 million people treated

Syndicated investment Projected funding: 1999 to

Leveraging donor funds MMV £ Pharma ‘in-kind’ £1.50 = total £3.50 Pharma ‘co-funding’ £1.00

TCP1TCP2TCP3aTCP3bTCP4 A Liver-stage schizonts B Blood-stage schizonts C Gametocytes D Micro- and Macro-gametes/zygotes E Ookinetes F Oocysts G Sporozoites P. cynomolgi hypnozoite assay BPRC, Netherlands P. yoelii/berghei liver stage assay GNF Novartis/ UCSD, USA P. yoelii/berghei liver stage assay GNF Novartis/ UCSD, USA In vitro blood stage activity Swiss TPH, Switzerland & Eskitis, Australia In vitro blood stage activity Swiss TPH, Switzerland & Eskitis, Australia Parasite Reduction Rate in vivo hu-SCID model GSK Tres Cantos, Spain Parasite Reduction Rate in vivo hu-SCID model GSK Tres Cantos, Spain Resistance risk assessment Columbia University, USA Resistance risk assessment Columbia University, USA Gametocycte and gamete formation assays Griffith University Australia and Imperial College UK Gametocycte and gamete formation assays Griffith University Australia and Imperial College UK Gametocycte assay GSK Tres Cantos, Spain Gametocycte assay GSK Tres Cantos, Spain Membrane feed assay Imperial College, UK Membrane feed assay Imperial College, UK Membrane feed assay TropIQ, Netherlands GSK, Tres Cantos Membrane feed assay TropIQ, Netherlands GSK, Tres Cantos MMV has assembled a network of partners/assays to select molecules with required properties Network of partners/assays Industry ● Academia ●

MMV–partnership pipeline Q1 2014

Focusing resources through early project prioritisation Before GLP preclinical GLP preclinicalPhase IPhase IIPhase IIILaunched Active Terminated

Reducing costs in clinical development INDUSTRY $180 MILLION Industry estimates for clinical development of an anti-infective (Tufts) MMV $54 MILLION* Total clinical development costs for pyronaridine-artesunate * Includes direct internal project costs, CRO costs and MMV management & administration costs. 70% REDUCTION

INITIAL COST PROPOSAL Reducing partner & vendor costs e.g. non-clinical toxicology study

INITIAL COST PROPOSAL CRO BID Reducing partner & vendor costs e.g. non-clinical toxicology study 73% REDUCTION

INITIAL COST PROPOSAL CRO BID MMV SHARE Reducing partner & vendor costs e.g. non-clinical toxicology study 50% OF CRO BID 13% OF INITIAL PROPOSAL

Access and affordability ACT 47% REDUCTION Terms of MMV alliance agreements +Obligation to launch in malaria-endemic countries +Price targets & cost audits

UK 23 pence* to treat one child * cost for one 3-day course of Coartem-dispersible (Novartis public sector price for malaria-endemic countries; weighted average treatment regimen 2012; March 1st 2013 exchange rate)

>212 million treatments delivered and counting

Coartem Dispersible million children cured 200 million treatment courses delivered * estimates based upon drug distribution data, epidemiology / testing data and clinical efficacy data (PCR-corrected 28-day cure rate for Coartem Dispersible)

Impact beyond malaria

Providing researchers with 400 anti-malaria compounds to further R&D in other NTDs

Providing researchers with 400 anti-malaria compounds to further R&D in other NTDs 3 chemical series

Providing researchers with 400 anti-malaria compounds to further R&D in other NTDs 2 tropical diseases Sleeping sickness Leishmaniasis

MMV is grateful for the financial support from the following organizations: 21